Trial Profile

A Phase 2 study of ONO-4538 in patients with stage IIIB/IV or recurrent non-squamous NSCLC

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary)
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use
Sponsors Ono Pharmaceutical

Most Recent Events

19 May 2022 Status changed from active, no longer recruiting to completed.
01 Jan 2021 Results of pooled analysis assessing the 5-year OS of patients enrolled in the ONO-4538-05 and ONO-4538-06 studies published in the Japanese Journal of Clinical Oncology
12 Feb 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com